DIRA 1.0: Atlas of Drug-induced Rhabdomyolysis

DESFLURANE

DIR Classification Postmarketing Surveillance Drug Property Information Reference

DIR Classification

Classification:Less-DIR concern

Severity Score:1

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

ADVERSE REACTIONS
Post-Marketing Experience
The following adverse reactions have been identified during post-approval use of SUPRANE. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and Lymphatic System Disorders: Coagulopathy
Metabolism and Nutrition Disorders: Hyperkalemia, Hypokalemia, metabolic acidosis
Nervous System Disorders: Convulsion, Post-operative agitation in children
Eye Disorders: Ocular icterus
Cardiac Disorders: Cardiac arrest, Torsade de pointes, ventricular failure, ventricular hypokinesia, atrial fibrillation
Vascular Disorders: Malignant hypertension, hemorrhage, hypotension, shock
Respiratory, Thoracic and Mediastinal Disorders: Respiratory arrest, respiratory failure, respiratory distress, bronchospasm, hemoptysis
Gastrointestinal Disorders: Pancreatitis acute, abdominal pain
Hepatobiliary Disorders: Hepatic failure, hepatic necrosis, hepatitis, cytolytic hepatitis, cholestasis, jaundice, hepatic function abnormal, liver disorder
Skin and Subcutaneous Tissue Disorder: Urticaria, erythema
Musculoskeletal, Connective Tissue and Bone Disorders: Rhabdomyolysis
General Disorders and Administration Site Conditions: Hyperthermia malignant, asthenia, malaise
Investigations: Electrocardiogram ST-T change, electrocardiogram T-wave inversion, tranaminases increased, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, coagulation test abnormal, ammonia increased
Injury, Poisoning, and Procedural Complications*: Tachyarrhythmia, palpitations, eye burns, blindness transient, encephalopathy, ulcerative keratitis, ocular hyperemia, visual acuity reduced, eye irritation, eye pain, dizziness, migraine, fatigue, accidental exposure, skin burning sensation, drug administration error
*Reactions categorized within this SOC were accidental exposures to non-patients.

Postmarketing Surveillance

Contingency Table:

Current Drug

Other Drugs

Rhabdomyolysis

42907

Other ADRs

640

14116639

Odds Ratio = 2.571

Drug Property Information

ATC Code(s):

N01AB07 - desflurane

N01AB - Halogenated hydrocarbons
N01A - "ANESTHETICS, GENERAL"
N01 - ANESTHETICS
N - NERVOUS SYSTEM

Active Ingredient:desflurane

Active Ingredient UNII:CRS35BZ94Q

Drugbank ID:DB01189

PubChem Compound:42113

CAS Number:57041-67-5

Dosage Form(s):liquid

Route(s) Of Administrator:respiratory (inhalation)

Daily Dose:

Chemical Structure:

SMILE Code:
C(C(F)(F)F)(OC(F)F)F

Reference

COHORT STUDY:

N/A

OTHER REFERENCE(S):

1: Malignant hyperthermia: a review.

[Rosenberg Henry,Pollock Neil,Schiemann Anja,Bulger Terasa,Stowell Kathryn]
Orphanet J Rare Dis.2015 Aug 4;10:93. doi: 10.1186/s13023-015-0310-1. PMID: 26238698

2: Delayed onset malignant hyperthermia after sevoflurane.

[Turhan K Sanem Cakar,Baytaş Volkan,Batislam Yeşim,Ozatamer Oya]
Case Rep Anesthesiol.2013;2013:712710. doi: 10.1155/2013/712710. Epub 2013 May 30. PMID: 23819066

3: Malignant hyperthermia.

[Rosenberg Henry,Davis Mark,James Danielle,Pollock Neil,Stowell Kathryn]
Orphanet J Rare Dis.2007 Apr 24;2:21. PMID: 17456235

4: Anesthetic effects on the glycerol model of rhabdomyolysis-induced acute renal failure in rats.

[Lochhead K M,Kharasch E D,Zager R A]
J Am Soc Nephrol.1998 Feb;9(2):305-9. PMID: 9527408

Search for drugs: